Geneseq Biosciences was founded in 2017 by Ryan Van Laar Ph.D, a translational genomics scientist with over 15 years of experience in designing, validating and performing clinically useful tests for cancer diagnosis, prognosis and treatment optimisation.
Dr Van Laar has over 20 peer-reviewed publications and has been involved in three successful FDA applications for novel genomic assays. A prior start-up, ChipDX.com, was acquired by Signal Genetics (New York) in 2012. Before founding Geneseq Biosciences, Ryan was Vice President of Research & Operations and Laboratory Director for Signal Genetics, based in Little Rock, Arkansas, USA.
The company was also co-founded by Barton Van Laar, a business strategy, marketing and communications specialist with over 40 years of cross-sector experience.
Australian Clinical Labs
Australian Clinical Labs and Geneseq Biosciences (Geneseq) partnered in 2018 to bring the first non-invasive melanoma test to market under the trademark Melaseq™.
Australian Clinical Labs combine pathology leadership, ground-breaking technology and the best scientists in the field to bring better outcomes for doctors and patients alike.
Clinical Labs is the largest pathology provider to public hospitals in Australia and one of the top choices amongst private practices across the country. With over 90 NATA accredited laboratories and 900 collection sites nation-wide, the company performs around 8 million episodes a year for a range of clients including doctors, specialists, patients, hospitals and corporate clients.
Clinical Labs is a leader in molecular testing and new technologies and employs over 3,800 employees including more than 90 highly respected and experienced pathologists.
For more information about Clinical Labs please see: www.clinicallabs.com.au
Geneseq values the contributions of our commercial partners: